FREMONT, Calif. and WALTHAM, Mass., Oct. 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq:ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that four tenapanor abstracts have been accepted for presentation at the American Society of Nephrology Kidney Week 2021 (ASN Kidney Week), which is taking place virtually November 4 - November 7, 2021. The accepted abstracts present new observations for tenapanor, a first-in-class phosphate absorption inhibitor which has completed three successful Phase 3 clinical trials for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor was discovered and developed by Ardelyx.
Read more at prnewswire.comArdelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.